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Introduction
Retinoblastoma, a relatively rare cancer, is the most common
intraocular tumour in childhood (1/15000) which mainly
affects children under the age of 6 years (Valverde et al.
2005). It is caused by mutations in the RB1 tumour suppres-
sor gene which occurs in both sporadic and familial forms.
In about half of the patients, one mutation is inherited via
the germinal cells, while in the remaining cases both muta-
tions occur in the somatic cells. Genetic analysis of RB1
may have a major impact on genetic counselling of fami-
lies with retinoblastoma, since preimplantation or prenatal
genetic diagnosis could be performed once the mutation was
identiﬁed (Noorani et al. 1996; Richter et al. 2003). Further,
unaffected at-risk individuals should be regularly monitored
with examination under anesthesia; however, if no mutation
was identiﬁed by genotyping, there is no longer need for
follow-up clinical visits.
The RB1 gene on chromosome 13q14 consists of 27
exons, spanning approximately 180 kb of genomic DNA
(Friend et al. 1986). So far, a wide range of alterations
have been identiﬁed in the RB1 gene (Richter et al. 2003;
Houdayer et al. 2004; Lohmann and Gallie 2004; Valverde
et al. 2005). Given the large size of RB1 and absences of hot
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spots or common mutations in the RB1, a full gene analysis is
difﬁcult and costly. Therefore, most diagnostic laboratories
prefer to carry out exon sequencing approaches which would
be expected to detect more than two-third of all mutations
in RB1 (Parsam et al. 2009). Nonsense mutations frequently
occur in 11 CGA codons (arginine) in the RB1 gene. These
mutations are primarily C to T transition, occurring at CpG
dinucleotide and consequently results in a change of CGA to
TGA stop codon (R to X mutations). These arginine alterations,
together with mutation of the donor splice site in intron 12
account for approximately one-third of all mutations in RB1
(Cowell et al. 1994; Lohmann 1999; Richter et al. 2003;
Valverde et al. 2005; Rushlow et al. 2009). Therefore, sim-
ple, rapid and reliable methods such as ampliﬁcation refrac-
tory mutation system (ARMS) PCR which could simultane-
ously analyse a sample for the presence of multiple mutations
would be useful. The aim of this study was to develop a mul-
tiplex ARMS-PCR method to screen for the most recurrent
mutations in RB1 in patients with retinoblastoma.
Materials and methods
Subjects
To investigate recurrent mutations of RB1 in retinoblastoma
patients, 121 children with sporadic or familial retinoblastoma
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Table 1. Primer sequences, fragment sizes and relevant point mutations of RB1 gene.
Mutation Primer name Sequence Length (bp)
R251X 251-f-M F: 5′-TGTTATACCCATTAATGGTTCACCCT-3′ 340
Com8 R: 5′-TCCAGAGTGAGGGAGCTACTCT-3′
R255X 255-s-M F: 5′-GTTCACCTCGAACACCCAGTT-3′ 322
Com8 R: 5′-TCCAGAGTGAGGGAGCTACTCT-3′
R320X Com10 F: 5′-ATTGCATGCGAACTCAGTGT-3′ 186
320-q-M R: 5′-CTTTATTTTTAAGATAAATTTCTTCGTATGA-3′
R358X 358-w-M F: 5′-TATTTAGTTTTGAAACACAGAGAACACCTT-3′ 154
Com11 R: 5′-CAAATCTGAAACACTATAAAGCCATGAATAAC-3′
R445X Com14 F: 5′-ATCCAGGTACTGGACCTACCC-3′ 394
445-v-M R: 5′-TACAAGCGAACTCCAAGTTTGTATTA-3′
R455X Com14 F: 5′-ATCCAGGTACTGGACCTACCC-3′ 426
455-q-M R: 5′-CTGATTTAAGCATGGATTCCATTACTGA-3′
R467X Com14 F: 5′-ATCCAGGTACTGGACCTACCC-3′ 872
467-q-M R: 5′-GTAAAAAATTTACCTAAAATTTTGAATGGATAATGA-3′
R551X Com17 F1 F: 5′-AATAGATATGCCAATGGCTGATAAG-3′ 483
551-q-M R-5′-TTCCATGATTCGATGTTCACATGA-3′
R556X Com17 F2 F-5′-TTTGTCTTTCCCATGGATTCTGAATG-3′ 157
556-q-M R: 5′-CCATGCAAGGGATTCCATGATTGA-3′
R579X Com18 F: 5′-TTTCTAATATAAGCGTTGAAGGTTATACAT-3′ 299
579-q-M R: 5′-GTGATCAGTTGGTCCTTCTGA-3′
R787X Com23 F: 5′-GCAGCTATAATCCAAGCCTAAGAAG-3′ 458
787-q-M R: 5′-AACTAGGAAACTTGTAAGGGCTTGA-3′
IVS12+1 Com12 F: 5′-GTGTATTTGAAGATACATTTAACTTGGG-3′ 225
IVS12-j-M R: 5′-ATTACAATAAATAATGTTTCATATATGGCTTCT-3′
Control Forward F: 5′-CCAAGTGACAAATAGCAAGTGTT-3′ 600
Reverse R: 5′-AGATATTCTGCAAGTACAATCACATT-3′
were recruited from the Farabi, Rasool-Akram and Mahak
hospitals in Tehran, Iran. The study was approved by the Avi-
cenna Research Institute’s ethics and human rights commit-
tee. The parents and guardians of all patients were consulted
and a written informed consent was obtained.
DNA extraction
From each subject, 5 mL of peripheral blood was collected in
EDTA containing tube and DNA was extracted by standard
salting out protocol (Miller et al. 1988).
Designing of primer for ARMS-PCR
Normal and mutant-speciﬁc primers were designed for each
point mutation, including R251X, R255X, R320X, R358X,
R445X, R455X, R467X, R551X, R556X, R579X, R787X
and IVS12+1. ARMS-PCR primers were designed accord-
ing to the approaches used by Ferrie et al. (1992). To
increase the speciﬁcity of ARMS assays, additional mis-
matches were included in the penultimate bases of mutant
ARMS primers. Therefore, purine/pyrimidine mismatches in
the penultimate positions were preferentially selected, due
to the fact that certain mismatches have a less destabilizing
effect. Presence of mismatches at the 3′ end of the mutant-
speciﬁc primers decreases the ampliﬁcation of normal DNA
sequences to the minimum possible extent because of the
destabilizing effect. However, despite this general rule, some
primers with purine/pyrimidine mismatches in the penulti-
mate position may amplify both normal and mutant DNA
sequences. To overcome this problem, the purine/purine or
pyrimidine/pyrimidine mismatches were obligatorily used.
On the other hand, to avoid false negative results in the
ARMS reactions and to ensure the ﬁdelity of the PCR ampli-
ﬁcation process, a pair of primers was used as an internal
control in each reaction. The internal control primers were
selected from chromosomal regions other than chromosome
13. Primer pairs which gave the best results are shown in
table 1.
Multiplex ARMS reaction conditions
The ARMS-PCR assays were optimized as three individual
multiplex reactions according to the annealing temperature
and location of each primer pair (table 2). Each multiplex
ARMS-PCR reaction contained: 2.5 μL 10× PCR Buffer
(Roche, Berlin, Germany), 3 mM MgCl2, 2.5 mM of each
dNTP (Roche), 5 pmol of each relevant primer (table 3),
50 ng template DNA, 1 U Taq DNA polymerase (Roche) and
sterile distilled water to 25 μL. PCR was performed under
the following conditions: an initial denaturation at 94◦C for
5 min, followed by 35 ampliﬁcation cycles of 94◦C for 30 s,
57–61◦C for 1 min and 72◦C for 1 min, with a ﬁnal exten-
sion of 72◦C for 5 min (table 2). PCR products were sep-
arated on 2% agarose gel containing ethidium bromide and
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Table 2. Multiplex ARMS-PCR reactions and the condition of
each reaction.
Exon Length Annealing
Reaction Mutation number (bp) temperature
Multiplex 1 R255X 8 322 61
R358X 11 154
R445X 14 399
R455X 14 426
R467X 15 872
Control – 600
Multiplex 2 R320X 10 186 57
R551X 17 483
R579X 18 299
Control – 600
Multiplex 3 R251X 8 340 60
R556X 17 157
R787X 23 458
IVS12 12 225
Control – 600
visualized under UV light. All detected mutations were
conﬁrmed by direct sequencing. To ensure the ﬁdelity of
each multiplex ARMS-PCR assay, individual reactions were
tested on at least 50 different normal controls DNA.
Results
In the current study, 121 unrelated Iranian retinoblastoma
patients were analysed for the presence of 12 recurrent muta-
tions in RB1. Among these, 56 patients were unilateral and
65 patients had bilateral tumours. The mean age of patients
was 17.6 months, and it was 21.7 and 14.4 months for uni-
lateral and bilateral patients, respectively. ARMS-PCR reac-
tions were performed for all samples and mutations were
identiﬁed in 30 (24.8%) patients (ﬁgure 1; table 3). Among
the cases, two (out of 56) and 28 (out of 65) point mutations
(3.6% versus 43.1%) were found in patients with unilateral
and bilateral forms, respectively. According to our results,
Table 3. Mutations detected using new multiplex ARMS-PCR.
Mutation Bilateral patients Unilateral patients
p.R251X 2 0
p.R255X 1 0
p.R320X 2 0
p.R358X 2 0
IVS12+1G>T 0 2
p.R445X 5 0
p.R455X 1 0
p.R467X 3 0
p.R551X 2 0
p.R556X 2 0
p.R579X 4 0
p.R787X 4 0
Sum 28/65 = 43% 2/56 = 3.5%
the mutation detection rate in bilateral patients was signif-
icantly higher than unilateral ones (P < 0.02). All above-
mentioned mutations were conﬁrmed by direct sequencing.
However, in one sample with a R787X mutation sequencing
result was clearly normal.
Discussion
Rapid and cost-effective methods for mutation screening
are signiﬁcant factors for diagnostic laboratories (Noorani
et al. 1996). Today, mutations are detected by an increasing
number of methods, ranging from genomic restriction frag-
ment length polymorphism (RFLP) to next generation whole
genome sequencing approaches. However, each of these
techniques has its own advantages and limitations. In many
genetic disorders, the responsible mutations can be detected
easily, because there are relatively few common mutations in
speciﬁc ethnic populations. In contrast, in some single gene
disorders, for example, retinoblastoma a wide variety of dif-
ferent mutations spread throughout the gene are implicated.
This makes mutation analysis very difﬁcult, and therefore a
technique which could simultaneously detect multiple muta-
tions would be useful (Valverde et al. 2005; Rushlow et al.
2009; Ahani et al. 2011).
Figure 1. Mutations detected by ARMS-PCR assay. A, B and C depict the results of multiplex ARMS-PCR reactions
1, 2 and 3, respectively. (1) R358X, (2) R255X, (3) R445X, (4) R455X, (5) R467X, (6) R320X, (7) R579X, (8) R551X,
(9) R556X, (10) IVS12+1, (11) R251X, (12) R787X; M, marker size 100 bp. The arrows show internal control bands.
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RB1 is a relatively large gene, and to date many different
mutations have been identiﬁed in all its exons. The presence
of multiple unique mutations together with the absence of
mutational hot spots in the RB1 gene, making genetic testing
complex and challenging, and accordingly, the entire coding
region and ﬂanking sequences should be analysed. However,
some recurrent mutations in 11 CGA codons of RB1 have
been reported by several investigators (Cowell et al. 1994;
Lohmann 1999; Houdayer et al. 2004; Bamne et al. 2005;
Taylor et al. 2007; Rushlow et al. 2009; Chen et al. 2010;
Ahani et al. 2011). Most sporadic bilateral patients carry a
constitutional mutation. In the literature, the mutation detec-
tion rate for sporadic bilateral and unilateral patients are 60–
90% and 10–20%, respectively. The frequency of constitu-
tional mutations in unilateral patients is lower than bilateral,
since they may have mosaic mutations which cannot not be
detected in blood samples (Richter et al. 2003; Houdayer
et al. 2004; Valverde et al. 2005).
In the current study, a simple ARMS-PCR method was
designed for rapid screening of the recurrent mutations in
RB1. One hundred and twenty-one patients were analysed by
ARMS-PCR and totally 12 different mutations were detected
in 30 patients (24.8%). Mutation detection rates in the unilat-
eral and bilateral cases were 3.6% (2/56) and 43.1% (28/65),
respectively. There was a signiﬁcant difference in mutation
detection rate between the bilateral and unilateral retinoblas-
toma, which could be explained by different penetrance of
germ-line mutations. Based on previous studies, some RB1
mutations such as nonsense mutations have a complete pen-
etrance, which usually lead to bilateral multifocal retinoblas-
toma. In contrast, mutations that disrupt splicing or alter
promoter function as well as missense mutations that occur
outside the pocket domains of pRb, have a reduced pen-
etrance (Lefevre et al. 2002; Valverde et al. 2005; Taylor
et al. 2007; Zhang et al. 2008; Abouzeid et al. 2009). These
types of mutations usually result in unilateral retinoblastoma
which may be unifocal or multifocal. Similarly, in two uni-
lateral cases from this study, mutation in the donor splice site
of intron 12 (IVS12+1) was detected; whereas, all the 28
detected mutations in bilaterals were nonsense (table 3).
To our knowledge, PCR-based methods for detection of
common mutations in RB1 have been reported in only few
studies (Richter et al. 2003; Rushlow et al. 2009). The impor-
tance of PCR-based techniques for mutation detection in
retinoblastoma has recently been shown by Rushlow et al.
(2009). They found mutations in 92.6% of the cases by a
combination of sequencing (for detection of point mutations)
and deletions/duplications analysis of RB1. Moreover, addi-
tional mutations in the cases with clearly normal sequenc-
ing results were found by PCR-based methods, so the detec-
tion rate increased to 94.8%. This could be explained by
low-level mosaicism; when only low percentages of lym-
phocytes carry a mutation, depending on the proportion of
mutated cells, it would be difﬁcult to detect a mutation
by direct sequencing. High normal background in sequenc-
ing results due to the presence of normal cells within the
sample can mask the presence of mutations. PCR-based
mutation detection methods have a relatively high sensitiv-
ity, so that in samples with low-level mosaicism mutant alle-
les can be speciﬁcally detected. Similarly, we found a R787X
mutation by ARMS-PCR assay, whereas the sequencing
result for exon 23 of RB1 in this patient was clearly normal.
Recurrent mutations in RB1 in 20–40% of patients (in
this study, 43% of bilateral patients) could be screened by
ARMS-PCR, which can be considered as a rapid and cost-
effective technique. As mentioned above, the entire cod-
ing region should be screened to detect other mutations in
RB1. However, some relatively large rearrangements, includ-
ing deletions and duplications, ranging from single exon
to whole gene deletion, account for approximately 10–20%
of the total mutations in RB1. Nowadays, such large rear-
rangements can be detected by multiplex ligation-dependent
probe ampliﬁcation (MLPA). By a combination of MLPA
and ARMS-PCR assays in routine genetic analysis, muta-
tion detection rate may increase to 30–50%. Therefore, these
approaches can detect RB1 mutations in about half of the
patients within a short time. If no mutations were detected by
ARMS-PCR and MLPA, the whole coding region should be
sequenced.
In conclusion, we suggest that ARMS-PCR as a sim-
ple, reliable, rapid, and cost-effective technique, could be
used in the ﬁrst step of genetic analysis in patients with
retinoblastoma.
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